Incannex Healthcare received the Research and Development Award in the Respiratory Disorders category of the 2025 Clinical Trials Arena Excellence Awards for its work advancing IHL-42X, an oral fixed-dose combination product candidate for obstructive sleep apnea.
IHL-42X combines dronabinol and acetazolamide and is designed for adults with moderate-to-severe OSA, a chronic disorder predominantly managed with device-based therapies such as positive airway pressure machines. Many patients remain untreated or undertreated due to intolerance, poor adherence, or reluctance to use nightly devices. The company’s development strategy targets underlying sleep-respiratory physiology, with a dual-component regimen designed to stabilize ventilatory control and improve upper airway muscle function, offering a potential non-invasive pharmacologic alternative.
Incannex’s Phase 2 clinical program demonstrated favorable safety and tolerability, supporting continued development for potential chronic use if approved. The study integrated objective polysomnography outcomes, validated patient-reported measures, and structured exit interviews. “We are honored to be recognized by the Clinical Trials Arena Excellence Awards for the deliberate, science-driven approach we have taken with IHL-42X,” said Joel Latham, President and CEO. “Obstructive sleep apnea continues to be an area of significant unmet medical need, particularly for patients who struggle with long-term adherence to device-based therapies.”
The Clinical Trials Arena Excellence Awards, powered by GlobalData’s business intelligence, analyzed more than one billion datasets annually to identify leading companies across more than 200 countries. Incannex’s broader pipeline also includes IHL-675A for rheumatoid arthritis and PSX-001 for generalized anxiety disorder, both in Phase 2 development.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.benzinga.com/pressreleases/26/01/g49931591/incannex-healthcare-wins-research-and-development-award-for-obstructive-sleep-apnea-program-in-the